Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Drugs
Published in: Pediatric Drugs 6/2008

01-11-2008 | Commentary

Drug Delivery Systems in Children

Author: Dr Stephen Lowis

Published in: Pediatric Drugs | Issue 6/2008

Login to get access

Excerpt

The efficacy of a given drug is dependent upon the reliability of delivery to its site of action; the drug must reach its target to have an effect. At the simplest level, the preparation of a drug, its route of administration, and its disposition according to pharmacokinetic properties define its delivery; these factors are particularly important in pediatric practice. For the last 20 years, modification of drug disposition has been possible, and a number of specific delivery systems have appeared with this in mind. Examples include polymeric carriers, reservoirs and matrix devices, liposomal preparations, and modification of molecules to influence their antigenicity. Selective targeting of carrier molecules, to deliver a chosen drug to its site of action, has been attempted. All of these strategies aim to improve activity or reduce toxicity. …
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement
 
Literature
1.
Nowak-Gottl U, Heinecke A, von Kries R, et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001 Aug 1; 103(3): 165–72PubMedCrossRef
2.
Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896–904PubMedCrossRef
3.
Rodriguez T, Baumgarten E, Fengler R, et al. Long-term infusion of L-as-paraginase: an alternative to intramuscular injection? [in German]. Klin Padiatr 1995; 109(4): 207–10CrossRef
4.
Tuttle CB. Intramuscular injections and bioavailability. Am J Hosp Pharm 1977 Sep; 34(9): 965–8PubMed
5.
Ellison JA, Patel L, Ray DW, et al. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000 Apr; 105 (4 Pt 1): 794–9PubMedCrossRef
6.
Ozon A, Cetinkaya S, Alikasifoglu A, et al. Inappropriate use of potent topical glucocorticoids in infants. J Pediatr Endocrinol Metab 2007 Feb; 20(2): 219–25PubMedCrossRef
7.
Guven A, Gulumser O, Ozgen T. Cushing’s syndrome and adrenocortical insufficiency caused by topical steroids: misuse or abuse? J Pediatr Endocrinol Metab 2007 Nov; 20(11): 1173–82PubMedCrossRef
8.
Osorio JE, Zuleger CL, Burger M, et al. Immune responses to hepatitis B surface antigen following epidermal powder immunization. Immunol Cell Biol 2003 Feb; 81(1): 52–8PubMedCrossRef
9.
Wolf AR, Stoddart PA, Murphy PJ, et al. Rapid skin anaesthesia using high velocity lignocaine particles: a prospective placebo controlled trial. Arch Dis Child 2002 Apr; 86(4): 309–12PubMedCrossRef
10.
Burkman RT. Transdermal hormonal contraception: benefits and risks. Am J Obstet Gynecol 2007; 134: e1–6
11.
Hunt A, Goldman A, Devine T, et al. Transdermal fentanyl for pain relief in a paediatric palliative care population. Palliat Med 2001; 15: 405–12PubMedCrossRef
12.
Horimoto Y, Tomie H, Hanzawa K, et al. Scopolamine patch reduces postoperative emesis in paediatric patients following strabismus surgery. Can J Anaesth 1991; 38: 441–4PubMedCrossRef
13.
Zernikow B, Michel E, Anderson B. Transdermal fentanyl in childhood and adolescence: a comprehensive literature review. J Pain 2007; 8: 187–207PubMedCrossRef
14.
Collins JJ, Dunkel IJ, Gupta SK, et al. Transdermal fentanyl in children with cancer pain: feasibility, tolerability, and pharmacokinetic correlates. J Pediatr 1999; 134: 319–23PubMedCrossRef
15.
Power I. Fentanyl HCl iontophoretic transdermal system (ITS): clinical application of iontophoretic technology in the management of acute postoperative pain. Br J Anaesth 2007 Jan; 98(1): 4–11PubMedCrossRef
16.
Halhal M, Renard G, Courtois Y, et al. Iontophoresis: from the lab to the bed side. Exp Eye Res 2004 Mar; 78(3): 751–7PubMedCrossRef
17.
Fujimoto T. Pharmacokinetics of intrathecal chemotherapy and clinical problems [in Japanese]. Gan To Kagaku Ryoho 1984 Aug; 11(8): 1536–42PubMed
18.
Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975 Jul 24; 293(4): 161–6PubMedCrossRef
19.
Bleyer WA, Poplack DG. Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 1979; 6(3): 207–13PubMedCrossRef
20.
Phuphanich S, Maria B, Braeckman R, et al. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 2007 Jan; 81(2): 201–8PubMedCrossRef
21.
Biggart E, Bush A. Antiasthmatic drug delivery in children. Paediatr Drugs 2002; 4(2): 85–93PubMed
22.
Sermet-Gaudelus I, Le Cocguic Y, Ferroni A, et al. Nebulized antibiotics in cystic fibrosis. Paediatr Drugs 2002; 4(7): 455–67PubMed
23.
Cheer SM, Warner GT, Easthope SE. Formoterol delivered by Turbuhaler: in pediatric asthma. Paediatr Drugs 2003; 5(1): 63–8 discussion 9PubMed
24.
De Benedictis FM, Selvaggio D. Use of inhaler devices in pediatric asthma. Paediatr Drugs 2003; 5(9): 629–38PubMedCrossRef
25.
Gulliver T, Morton R, Eid N. Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. Paediatr Drugs 2007; 9(3): 185–94PubMedCrossRef
26.
Mitchell JP, Coppolo DP, Nagel MW. Electrostatics and inhaled medications: influence on delivery via pressurized metered-dose inhalers and add-on devices. Respir Care 2007 Mar; 52(3): 283–300PubMed
27.
Wildhaber JH, Waterer GW, Hall GL, et al. Reducing electrostatic charge on spacer devices and bronchodilator response. Br J Clin Pharmacol 2000 Sep; 50(3): 277–80PubMedCrossRef
28.
Vaghi A, Berg E, Liljedahl S, et al. In vitro comparison of nebulised budesonide (Pulmicort respules) and beclomethasone dipropionate (Clenil per aerosol). Pulm Pharmacol Ther 2005; 18(2): 151–3PubMedCrossRef
29.
Barry PW, O’Callaghan C. The output of budesonide from spacer devices assessed under simulated breathing conditions. J Allergy Clin Immunol 1999 Dec; 104(6): 1205–10PubMedCrossRef
30.
O’Callaghan C, White J, Jackson J, et al. Delivery of nebulized budesonide is affected by nebulizer type and breathing pattern. J Pharm Pharmacol 2005 Jun; 57(6): 787–90PubMedCrossRef
31.
Zindani GN, Streetman DD, Streetman DS, et al. Adherence to treatment in children and adolescent patients with cystic fibrosis. J Adolesc Health 2006; 38: 13–7PubMedCrossRef
32.
Garvie PA, Lensing S, Rai SN. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS. Pediatrics 2007; 119: e893–9PubMedCrossRef
33.
Sparreboom A, van Tellingen O, Nooijen WJ, et al. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996 May 1; 56(9): 2112–5PubMed
34.
Buggins TR, Dickinson PA, Taylor G. The effects of pharmaceutical excipients on drug disposition. Adv Drug Deliv Rev 2007 Dec 22; 59(15): 1482–503PubMedCrossRef
35.
Fanta S, Jonsson S, Backman JT, et al. Developmental pharmacokinetics of ciclosporin: a population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol 2007 Dec; 64(6): 772–84PubMed
36.
Pollard SG. Pharmacologic monitoring and outcomes of cyclosporine. Transplant Proc 2004 Mar; 36(2 Suppl.): 404S–7SPubMedCrossRef
37.
Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc 2004 Mar; 36(2 Suppl.): 378S–91SPubMedCrossRef
38.
Dubus JC, Anhoj J. A review of once-daily delivery of anti-asthmatic drugs in children. Pediatr Allergy Immunol 2003; 14: 4–9PubMedCrossRef
39.
Lonnerholm G, Foucard T, Lindstrom B. Treatment of chronic asthma in children with a sustained-release preparation of theophylline in addition to beta 2-stimulating agents. Eur J Respir DisSuppl 1980; 109: 95–7
40.
Genton P. Progress in pharmaceutical development presentation with improved pharmacokinetics: a new formulation for valproate. Acta Neurol Scand Suppl 2005; 182: 26–32PubMedCrossRef
41.
Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Pshychiatry 2001; 40: 307–14CrossRef
42.
Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002; 49Suppl. 1: 21–30PubMedCrossRef
43.
Forssen EA, Ross ME. DaunoXome treatment of solid tumours: preclinical and clinical investigations. J Liposome Research 1994; 4: 481CrossRef
44.
Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 1992 Jun 15; 52(12): 3255–61PubMed
45.
Brown LR, Edelman ER, Fischel-Ghodsian F, et al. Characterization of glucose-mediated insulin release from implantable polymers. J Pharm Sci 1996 Dec; 85(12): 1341–5PubMedCrossRef
46.
Gupta P, Vermani K, Garg S. Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov Today 2002 May 15; 7(10): 569–79PubMedCrossRef
47.
Bourges JL, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 2006 Nov 15; 58(11): 1182–202PubMedCrossRef
48.
Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006 Jun; 113(6): 1020–7PubMedCrossRef
49.
Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev 2008; 60: 1037–55PubMedCrossRef
50.
Drin G, Rousselle C, Scherrmann JM, et al. Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors. AAPS PharmSci 2002; 4: E26PubMedCrossRef
51.
Day FH, Zhang Y, Clair P, et al. Induction of antigen-specific CTL responses using antigens conjugated to short peptide vectors. J Immunol 2003 Feb 1; 170(3): 1498–503PubMed
52.
Rousselle C, Clair P, Lefauconnier JM, et al. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 2000 Apr; 57(4): 679–86PubMed
Metadata
Title
Drug Delivery Systems in Children
Author
Dr Stephen Lowis
Publication date
01-11-2008
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 6/2008
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.2165/0148581-200810060-00002

Other articles of this Issue 6/2008

Pediatric Drugs 6/2008 Go to the issue

Original Research Article

Probability of Achieving Requisite Pharmacodynamic Exposure for Oral β-Lactam Regimens against Haemophilus influenzae in Children

Therapy In Practice

Treatment Strategies for Methicillin-Resistant Staphylococcus aureus Infections in Pediatrics

Original Research Article

Establishing Causality of CNS Depression in Breastfed Infants Following Maternal Codeine Use

Acknowledgments

Acknowledgment

Therapy In Practice

Management of Acute Kidney Injury in Children

Therapy In Practice

Management Strategies for Hepatitis C Virus Infection in Children